Compare Ally Financial Inc (ALLY) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Ally Financial Inc trades at $43.8 (market cap $13.37B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.02 (market cap $9.43B). The key difference: Ally Financial Inc is the larger of the two by market cap, and Ally Financial Inc pays a 2.73% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| ALLY | BIO | |
|---|---|---|
Market Cap | $13.37B | $9.43B |
Sector | Financials | Health |
52-Week High | $47.25 | $356.25 |
52-Week Low | $35.96 | $241.71 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.79, showing modest daily gains of 0.16%. The stock presents a compelling valuation with a P/E of 10.34 and P/B of 0.99, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations despite revenue growth, while technical indicators show bearish momentum with the stock trading near key support levels. The company maintains strong institutional support with 68% analyst buy ratings and recently declared a $0.30 dividend.
Ally offers value investment potential with attractive valuation metrics and solid dividend yield, though near-term headwinds include recent earnings miss and bearish technical signals. The auto finance business faces credit risk concerns amid economic uncertainty, but long-term digital banking leadership and improving margins provide growth catalysts. Upside potential exists if the company can maintain credit quality while expanding its digital banking footprint.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
